We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Silence Therapeutics Plc | LSE:SLN | London | Ordinary Share | GB00B9GTXM62 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 535.00 | 521.00 | 524.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMSLN
RNS Number : 7333I
Silence Therapeutics PLC
15 December 2020
TR-1: Standard form for notification of major holdings
1a. Identity of the issuer or the underlying issuer of existing shares to which voting Silence Therapeutics Plc rights are at- tached ii : 1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate) Non-UK issuer ------------------ 2. Reason for the notification (please mark the appropriate box or boxes with an "X") An acquisition or disposal of voting rights ------------------ An acquisition or disposal of financial instruments ------------------ An event changing the breakdown of voting rights X ------------------ Other (please specify)(iii) : ------------------ 3 . D e t a i ls of p ers on s ub j ect to t he no t i f i c a t i on ob li g a t i on iv Name Robert Quested ------------------------------------------------------------------ City and country of registered office (if applicable) ------------------------------------------------------------------ 4 . Fu ll n ame of s h are hold er( s) (i f d i f f e r e nt f r om 3. ) v Name ------------------------------------------------------------------ City and country of registered office (if applicable) ------------------------------------------------------------------ 5. Date on which the threshold was 10(th) December 2020 crossed or reached vi : ------------------------------------------------------------------ 6. Date on which issuer notified 14(th) December 2020 (DD/MM/YYYY): ------------------------------------------------------------------ 7. Total positions of person(s) subject to the notification obligation % of voting rights % of voting rights Total number at- tached to through financial Total of both of voting rights shares (to- tal instru- ments in % (8.A + 8.B) of is- suer of 8. A) (total of 8.B 1 vii + 8.B 2) ---------------------- ---------------------- ---------------------- ------------------ Resulting situation on the date on which threshold was crossed or reached 9.52% 83,306,259 ---------------------- ---------------------- ---------------------- ------------------ Position of previous notification (if applicable) 10.72% ---------------------- ---------------------- ---------------------- ------------------ 8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii A: Voting rights attached to shares Class/type of Number of voting rights ix % of voting rights --------------------------------------------------- ------------------------------------------------------ shares Direct Indirect Direct Indirect ISIN code (if (Art 9 of Directive (Art 10 of Directive (Art 9 of Directive (Art 10 of Directive possible) 2004/109/EC) 2004/109/EC) 2004/109/EC) (DTR5.1) 2004/109/EC) (DTR5.1) (DTR5.2.1) (DTR5.2.1) ------------------------ ------------------------- --------------------------- ------------------------- GB00B9GTXM62 7,930,279 0 9.52% 0.00% ------------------------ ------------------------- --------------------------- ------------------------- SUBTOTAL 8. A 7,930,279 9.52% --------------------------------------------------- ------------------------------------------------------ B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a)) Number of voting Type of financial Expiration Exercise/ Conversion rights that may be % of voting rights in- strument date x Period xi acquired if the instrument is exercised/converted. ------------- ----------------------- ---------------------------- --------------------- SUBTOTAL 8. B 1 ----------------------- ---------------------------- --------------------- B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b)) Type of financial Expiration Exercise/ Physical or Number of instrument date x Conversion cash settlement voting rights % of voting rights Pe- riod xi xii ----------- ------------- ----------------- --------------- --------------------- SUBTOTAL 8.B.2 ----------------- --------------- --------------------- 9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an "X") Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer(xiii) ---------------------------- Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity(xiv) (please add additional rows as necessary) ---------------------------- % of voting rights % of voting rights Total of both if if it equals or is through financial it equals or is higher N a me xv higher than the notifiable in- struments if than the notifiable threshold it equals or is higher threshold than the notifiable threshold ---------------------------------- ----------------------------- ------------------------------ 10. In case of proxy voting, please identify: Name of the proxy holder The number and % of voting rights held The date until which the voting rights will be held Place of completion UK Date of completion 14(th) December 2020 ---------------------
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
HOLUVUURRAUUAAA
(END) Dow Jones Newswires
December 15, 2020 07:28 ET (12:28 GMT)
1 Year Silence Therapeutics Chart |
1 Month Silence Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions